<i>LNX1</i> Contributes to Cell Cycle Progression and Cisplatin Resistance

• Main Authors: Minsu Jang, Rackhyun Park, Yea-In Park, Yeonjeong Park, Jin I. Lee, Sim Namkoong, Eun-Ju Lee, Junsoo Park
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: Cancers
• Subjects: <i>LNX1</i>; cell cycle; cisplatin; cell death
• Online Access: https://www.mdpi.com/2072-6694/13/16/4066

The ligand of numb-protein X1 (<i>LNX1</i>) acts as a proto-oncogene by inhibiting <i>p53</i> stability; however, the regulation of <i>LNX1</i> expression has not been investigated. In this study, we screened chemicals to identify factors that potentially regulate <i>LNX1</i> expression. We found that <i>LNX1</i> expression levels were decreased by DNA damage, including that by cisplatin. Upon treatment with lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA), <i>LNX1</i> expression levels increased. In addition, cell-cycle progression increased upon <i>LNX1</i> expression; the levels of S and G2/M populations were correlated with <i>LNX1</i> expression. Moreover, in CRISPR-Cas9-mediated <i>LNX1</i> knockout cells, we observed a delay in cell-cycle progression and a downregulation of genes encoding the cell-cycle markers cyclin D1 and cyclin E1. Finally, the upregulation of <i>LNX1</i>-activated cell-cycle progression and increased resistance to cisplatin-mediated cell death. Taken together, these results suggest that <i>LNX1</i> contributes to cell-cycle progression and cisplatin resistance.